Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
复制标题
DOI:
10.1371/journal.pone.0121177
复制
发表时间:
2015
期刊:
影响因子:
3.7
通讯作者:
Kuriyan J
中科院分区:
文献类型:
--
作者:
Zorn JA;Wang Q;Fujimura E;Barros T;Kuriyan J
More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib. FLT3 with quizartinib bound adopts an “Abl-like” inactive conformation with the activation loop stabilized in the “DFG-out” orientation and folded back onto the kinase domain. This conformation is similar to that observed for the uncomplexed intracellular domain of FLT3 as well as for related receptor tyrosine kinases, except for a localized induced fit in the activation loop. The co-crystal structure reveals the interactions between quizartinib and the active site of FLT3 that are key for achieving its high potency against both wild-type FLT3 as well as a FLT3 variant observed in many AML patients. This co-complex further provides a structural rationale for quizartinib-resistance mutations.
登录
查看更多内容
影响因子:
2.1
作者:
Levis, M;Small, D
通讯作者:
Small, D
影响因子:
5.8
作者:
Pronk, Sander;Pall, Szilard;Lindahl, Erik
通讯作者:
Lindahl, Erik
DOI:
10.1107/s0907444904019158
发表时间:
2004-12-01
影响因子:
2.2
作者:
Emsley, P;Cowtan, K
通讯作者:
Cowtan, K
影响因子:
14.8
作者:
Liu, Y;Gray, NS
通讯作者:
Gray, NS
DOI:
10.1107/s0907444909052925
发表时间:
2010-02
期刊:
Acta crystallographica. Section D, Biological crystallography
影响因子:
--
作者:
Adams PD;Afonine PV;Bunkóczi G;Chen VB;Davis IW;Echols N;Headd JJ;Hung LW;Kapral GJ;Grosse-Kunstleve RW;McCoy AJ;Moriarty NW;Oeffner R;Read RJ;Richardson DC;Richardson JS;Terwilliger TC;Zwart PH
通讯作者:
Zwart PH